We are studying the roles of Machine Learning and Artificial Intelligence in oncology. We are part of Metiska Farma, a pharmaceutical company based in Indonesia (metiska.co.id).
Cancer is an extremely complex disease which resulted from a constellation of mutations and epigenetic changes. To make sense of this complexity, we agglomerate it into distinct phenotypes, for example a HER2+ phenotype in breast cancer, in order to diagnose and create treatments for it. This ‘funneling’ of genomic and epigenomic changes to phenotypes masks the true nature of cancer and may explain the inefficacy of certain treatments to different patients.
We believe that to study such heterogeneity requires Machine Learning. We will start with images: from pathology, CT and MRI and connect them to sequencing and expression analysis. Along the way we will document different learning experience and summarize published reports.
We hope we can positively contribute to our shared fight with cancer.
Metiska Oncology team